HeartFlow Reaches $35, Testing Top of Trading Range

HeartFlow shares traded at $35 Tuesday, up from $26 in March and pressing against the high end of the $20 to $40 range that has contained the stock since late last year. The climb comes without a new product clearance or partnership announcement. The move reflects a continuation of the upward momentum that started in March, when the stock bottomed near $26, according to a Seeking Alpha analysis.

The $35 level has acted as resistance twice before, in December and again in February. Each prior test ended with a pullback. This time the stock has held above $35 for multiple sessions. The next few trading days will determine whether the breakout holds or the range caps the move again.

Traders who bought the March dip near $26 are sitting on gains of roughly 35%. New buyers at $35 face a different risk profile. A decisive move above $40 would open the path to higher prices. A rejection at $35 and a drop below $30 would negate the bullish pattern.

The stock remains a single-product medtech company whose revenue depends on hospital adoption and reimbursement decisions. Those drivers move slowly. The price action is outpacing the fundamental news flow, which means the stock is pricing in future volume growth that has not yet been confirmed.

HeartFlow closed Tuesday at $35. The level is the next test for the stock's rally.